Switzerland-based Vifor Pharma
and Germany-based Evotech AG have collaborated for the development and
discovery of new treatments for kidney diseases.
The launch of a new 50:50 joint venture will be focused on developing nephrology pipeline utilizing Evotec’s UK kidney biobank, NURTuRE. Under the terms of the agreement, Evotec will influence Vifor’s kidney diseases pipeline by existing product profiles as well as developing new ones.
Evotec plans to out licence all
of its assets developed under the venture to Vifor Pharma for the further registration
and commercialisation of the products hence expanding Vifor Pharma Group’s
strong nephrology pipeline.
Vifor...
